<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046186</url>
  </required_header>
  <id_info>
    <org_study_id>MS-SGRYGB-15</org_study_id>
    <nct_id>NCT03046186</nct_id>
  </id_info>
  <brief_title>Physiological Effects of Gastric Sleeve Operation</brief_title>
  <official_title>Effect of Gastric Sleeve Operation on Absorption and Metabolism of Glucose and Protein as Well as Gut-hormonal Response - A Comparison With Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After gastric sleeve patients undergo a substantial weight loss, but the physiological&#xD;
      mechanisms behind the weight loss is not fully elucidated. Studies suggest that gut-hormone&#xD;
      secretion is altered comparable to what is also seen after Roux-en-Y gastric bypass, however&#xD;
      to which extent is not fully established and furthermore, the mechanisms behind an altered&#xD;
      secretion are unclear. The purpose of this study is to investigate absorption and&#xD;
      postprandial metabolism of glucose and protein in addition to gut hormonal responses after&#xD;
      gastric sleeve compared with a group of un-operated subjects machted on sex, age and BMI.&#xD;
      Furter, a group of Roux-en-Y gastric bypass operated patients matched on pre-operative BMI,&#xD;
      current BMI, sex and age will be included for comparison.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose absorption</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Between groups difference in peak Rate of appearance (Ra) of oral glucose tracer SG vs. CON</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein absorption</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Between groups difference in peak Ra of oral aminoacid tracer SG vs. CON</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose absorption</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Between group difference in peak Ra of oral glucose comparing SG vs. RYGB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein absorption</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Between groups differences in peak Ra of oral aminoacid tracer comparing SG vs. RYGB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose kinetics</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Between groups differences in AUC Ra of oral glucose tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein kinetics</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Between groups differences in AUC Ra of oral aminoacid tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>0 - 240 minutes</time_frame>
    <description>Between groups differences in iAUC of serum insulin and C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like Peptide 1 (GLP-1) secretion</measure>
    <time_frame>0 - 240 minutes</time_frame>
    <description>Between groups differences in iAUC of plasma concentration of GLP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent Insulinotropic Peptide (GIP)</measure>
    <time_frame>0 - 240 minutes</time_frame>
    <description>Between groups differences in iAUC of plasma concentration of GIP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin secretion</measure>
    <time_frame>0 - 240 minutes</time_frame>
    <description>Between groups differences in iAUC of plasma concentration of ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>0-240 minutes</time_frame>
    <description>Between groups differences in iAUC of plasma cncentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY</measure>
    <time_frame>0-240 minutes</time_frame>
    <description>Between groups differences in iAUC of plasma concentration of PYY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>-120 - 360 minutes</time_frame>
    <description>Calculated via double tracer tecnique both in the fasting and post prandial state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipolysis</measure>
    <time_frame>-120 - 360</time_frame>
    <description>Between groups differences in Rate of Disappearance of glycerol tracer.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Gastric sleeve operated subjects</arm_group_label>
    <description>12 patients who have undergone gastric sleeve operation &gt;12 month prior to inclution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Subjects</arm_group_label>
    <description>12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric bypass operated subjects</arm_group_label>
    <description>12 patients, who have undergone Roux-en-Y gastric bypass &gt;12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mixed meal test with double tracer technique</intervention_name>
    <arm_group_label>Control Subjects</arm_group_label>
    <arm_group_label>Gastric bypass operated subjects</arm_group_label>
    <arm_group_label>Gastric sleeve operated subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples during mixed meal test with double tracer tecnique using iv tracers&#xD;
      ([D2] Phenylalanine, [ring-D4]Tyrosine, [6,6-2H2]Glucose, [1,1,2,3,3-2H5]Glycerol, [15N2]Urea&#xD;
      and labelled oral tracers ([U13C6]glucose, intrinsically [ring-D5]Phenylalanine).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, who have undergone Roux-en-Y gastric bypass OR gastric sleeve operation &gt; 12&#xD;
        month prior to inclusion.&#xD;
&#xD;
        Matched un-operated control subjects.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        SG ang RYGB group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Uncomplicated RYGB or SG &gt; 12 month prior to inclusion&#xD;
&#xD;
          -  Weight stable (+/- 3 month the last month)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes (HbA1c&gt;48 or Fasting plasma-glucose&gt;6.1 mM)&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
&#xD;
          -  Inadequately treated thyroid disease&#xD;
&#xD;
          -  Serious heart or respiratory illness&#xD;
&#xD;
          -  Haemoglobin &lt; 6,5 mM.&#xD;
&#xD;
        Un-operated control group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior RYGB, SG or complicated upper gastrointestinal surgery&#xD;
&#xD;
          -  Diabetes (HbA1c&gt;48 or Fasting plasma-glucose&gt;6.1 mM)&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
&#xD;
          -  Inadequately treated thyroid disease&#xD;
&#xD;
          -  Serious heart or respiratory illness&#xD;
&#xD;
          -  Haemoglobin &lt; 6,5 mM.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Please Select</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Saur Svane</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Gastric sleeve</keyword>
  <keyword>Gastric bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

